Skip to content

To Better Understand the Most Important Factors for Patients When They Decide on the Type of Treatment They Receive for Muscle Invasive Bladder Cancer (MIBC).

Patients' Treatment Preferences For Muscle Invasive Bladder Cancer Cancer: A Discrete Choice Experiment

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05236218
Enrollment
60
Registered
2022-02-11
Start date
2022-07-20
Completion date
2024-01-01
Last updated
2023-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle Invasive Bladder Cancer, Patient Preference, Patient Satisfaction, Sexual Wellbeing, Surgery

Keywords

Muscle invasive bladder cancer, Patient Preference

Brief summary

Through our study, we aim to understand the most important factors for patients when they decide on the type of treatment they receive for MIBC. Our study consists of a discrete choice experiment (DCE): a type of questionnaire used to elicit preferences in the absence of data. DCEs are frequently used in oncological research to elicit preferences from participants without directly asking them to state their preferred options. Participants undertaking our DCE questionnaire will presented with a series of alternative hypothetical scenarios containing several variables or attributes (5), each of which may have a number of variations or levels.

Detailed description

The study will be conducted using validated and established protocols for undertaking DCEs. A literature review was undertaken to assess what the most important considerations where for patients when making decisions about the treatment they receive for MIBC. Using this literature search as a starting point, discussion groups with relevant healthcare professionals and service users were undertaken to decide on the final attribute and levels for the questions. Five attributes were selected through an iterative process - Body image, Life expectancy, Side-effects from treatment, Living as bladder cancer survivor, and Sexual wellbeing The study is divided into three stages: 1. Interviews with experienced healthcare professionals and service users to finalise attributes and levels to be used for the questionnaire 2. A representative sample of patients (\ 10) will be asked to complete the questionnaire in addition to a brief unstructured interview to assess understanding (e.g. readability and ease of completing the questionnaire) 3. Necessary changes based on feedback from the pilot study will be applied before the main study is carried out

Interventions

OTHERDiscrete Choice Experiment (DCE) Patients DCE Questionnaire

Discrete Choice Experiment (DCE) Patients

OTHERSemi-Structured Interview Patients Interview

First version of questionnaire (readability/comprehension check)

Sponsors

King's College London
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosed with MIBC cancer and currently undergoing treatment or have previously completed treatment for MIBC

Exclusion criteria

* Any of other type of bladder cancer (unknown, metastatic, or non muscle invasive bladder cancer)

Design outcomes

Primary

MeasureTime frame
Willingness to accept treatment attributes, and trade-offs between these, using a study-specific Discrete Choice Experiment (DCE) QuestionnaireThrough study completion, an average of 1 year (Discrete Choice Experiment (DCE) Questionnaire). Trade-off from Marginal Rate of Substitution calculate as percentage points (0 to 100). ]

Countries

United Kingdom

Contacts

Primary ContactSimon Hughes, MD
Simon.1.hughes@kcl.ac.uk+44 20 7188 3761
Backup ContactLiam Mannion
Liam.mannion@kcl.ac.uk+44 20 7140 5685

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026